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Background: The aim of this work was to establish recommendations for the medical follow-up of workers
currently or previously exposed to carcinogenic substances for the bladder.
Methods: A critical synthesis of the literature was conducted. Sectors of activity where workers are or were
exposed to carcinogenic substances for the bladder were listed and classified according to the level of bladder
cancer risk. Performances of techniques available for the targeted screening of bladder cancer were analysed,
including a simulation of results among high-risk populations in France.
Results: The risk level for the professional group and the latency period between the start of exposure and the
natural history of the disease were selected to define a targeted screening protocol. The NMP22BC test, exclusive
haematuria testing, and combinations of urine cytology with, respectively, the NMP22BC test and haematuria test,
generated an extremely high proportion of false positive results.
Conclusion: Urine cytology is the test that offers the best specificity. Although poor for all bladder cancer stages
and grades combined, its sensitivity is better for high grades, which require early diagnosis since late-stage cancers
are of very poor prognosis. These results suggest that urine cytology is currently the only technique suitable for
proposal within the context of a first line targeted screening strategy for occupational bladder cancer. An algorithm
summarising the recommended medical follow-up for workers currently or previously exposed to carcinogenic
substances for the bladder is proposed, based on the level of risk of bladder cancer.
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With an estimated incidence of 386,000 cases of bladder
cancer worldwide in 2008 and over 150,000 deaths, blad-
der cancer is the 9th cause of cancer in the world and
the 8th cause of death by cancer in men [1,2]. In France,
bladder cancer is the 7th cause of cancer and the 8th
cause of death by cancer in men, with an estimated inci-
dence of 10,729 cases in 2009, causing over 4,500 deaths
[3]. The annual incidence rates for this cancer in men* Correspondence: clin-b@chu-caen.fr
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unless otherwise stated.and women in France were respectively 14.7/100000 and
2.5/100000 in 2012 [4].
Besides tobacco smoking, occupational exposure to car-
cinogens is another major risk factor for bladder cancer.
Indeed, according to study results, the proportion of blad-
der cancers attributable to occupational exposure ranges
from 5 to 25% in men [5-8]. In 2001, the InVS (Institut de
Veille Sanitaire) estimated that, in France, 8 to 14% of in-
cident cases of bladder cancer and 10 to 14% of deaths
linked to this type of cancer in men were attributable to
occupational exposure, representing 625 to 1,110 incident
cases and 347 to 492 deaths by bladder cancer in 1999 [8].
The most frequent occupational sectors where excess
rates of bladder cancer are observed are those exposing
(or having exposed) workers to aromatic amines, nitrosa-
mines and polycyclic aromatic hydrocarbons (PAHs). In. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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use of carcinogens such as certain aromatic amines, and
although preference has been given to the use of certain
substitute products (e.g. bitumen instead of coal tar), cer-
tain industrial sectors remain implicated in exposure to
bladder carcinogens (in particular, those using o-toluidine,
o-tolidine, o-anisidine and MBOCA, and those using
products containing secondary amines likely to react with
nitrosating compounds). Priority must therefore be placed
on implementing primary preventive measures on these
sites.
The latency after the start of exposure to a carcino-
genic substance for the bladder is estimated between 14
and 26 years [9] and appears rarely to fall under 20 years
[10]. In the majority of cases, urothelial tumours appear
after the age of 60 years [2,11]. According to data from
the international literature on the subject, bladder cancer
screening in the general population is not recommended,
due, in particular, to the disease’s low prevalence [12].
Furthermore, no study has been conducted relying on
a sufficiently large sample of individuals to assess the
relevance of bladder cancer screening in high-risk popu-
lations. Nevertheless, according to an international panel
of experts (International Consensus Panel on Cytology
and Bladder Tumour Markers), reunited in 2005, indi-
vidual screening in high-risk subjects such as smokers,
occupationally-exposed subjects and subjects with a gen-
etic predisposition could be considered using, in particu-
lar, urinary makers associated or not with conventional
cytology [13].
Data from the literature on our knowledge of certain
occupational risk factors and dose–response relation-
ships are as yet limited, as it is on bladder cancer screen-
ing tools and protocols. We therefore deemed absolutely
necessary the compilation of a synthesis of available
data, in order to determine associated strategy(ies) suit-
able for recommendation.
We deemed necessary to assess the efficiency of new
techniques used in urology for the early diagnosis of blad-
der cancer recurrence, in order to rationalise medico-
professional monitoring modalities for subjects presenting
a high risk of bladder cancer.
The management of occupational carcinogenic risk for
the bladder relies on both a technical preventive ap-
proach (i.e. the implementation of preventive measures,
e.g. suppression or limitation of the exposure to occupa-
tional carcinogens) and on specific medical follow-up.
We deliberately focus here on this second aspect. In-
deed, the aim of this work was to define modalities for
the medical follow-up of workers currently or previously
exposed to carcinogenic substances for the bladder,
which are adapted to exposure situations and coherent
with current knowledge on dose–response relationships,
evolutive characteristics and therapeutic options for thetreatment of bladder cancer. We consequently defined
target populations depending on risk levels and proof
levels based on analysis of the scientific literature, to-
gether with the current more appropriate screening tool
and frequency of screening.Methods
Population concerned
These medical recommendations target all healthcare
professionals involved in primary and secondary preven-
tion of bladder cancer, to employers and to workers cur-
rently or previously exposed to carcinogenic substances
for the bladder, whether they are still active or not and
independently of their professional status.
Healthcare professionals include the occupational phy-
sician and the other members of the pluridisciplinary
occupational health team (occupational health nurse
and professionals involved in primary prevention of
occupational risks) during the worker’s period of pro-
fessional activity, then the general practitioner and/or
urologist, or other healthcare professionals (e.g. in oc-
cupational disease consultation centres - within the
context of post-occupational follow-up, oncology net-
works and anatomopathologists).Method
The subject of our study is vast and raises a number of
questions and sub-questions. Available scientific data are
highly dispersed and difficult to summarise; however, in
principle, the subject does not require the initiation of a
public debate. Furthermore, the most appropriate method
appeared to be the RPC "Clinical Practice Guidelines"
method, recommended by the HAS (French National
Authority for Health). Analysis and critical synthesis
of the scientific literature were conducted according
to principles of critical reading, in order to attribute a
level of scientific proof to each article, according to
the classification recommended by the HAS (Table 1).
No randomised studies of occupational risk factors are
usually conducted in the working environment. In con-
trast, there have been several "well-conducted" studies,
taking into account confounding factors and potential
dose–response relationships, together with a number of
studies with concordant results. We consequently con-
sidered that meta-analysis or systematic reviews on well-
conducted cohort studies offered level 1 scientific proof.
We considered that cohort studies which were "well-
conducted non-randomised studies" offered level 2 scien-
tific proof, whereas, case–control studies were considered
as offering level 3 scientific proof.
Due to a lack of available studies, recommendations
are based on expert consensus within the framework of
a work group after consultation with the reading group.
Table 1 Recommendation grading (according to the
"Guide d’analyse de la littérature et gradation des
recommandations" - Literature analysis and
recommendation grading guide, HAS, January 2000)
Level of scientific proof provided by the




● High-power randomised comparative studies A




● Decision analysis based on well-conducted
studies
Level 2
● Low-power randomised comparative studies B







Level 4 Low level of proof
● Comparative studies with major bias
● Retrospective studies
● Case series
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mum exposure duration associated with a high risk of
bladder cancer, when information was available, we
agreed upon:
– a moderate relative risk for bladder cancer, for
statistically significant relative risk (RR), odds ratio
(OR) or standardised mortality ratio (SMR) observed
in the scientific literature strictly above 1 and equal
to or below 2;
– a high relative risk for bladder cancer for statistically
significant RR, OR or SMR strictly above 2 and
equal to or below 5;
– and a very high relative risk for bladder cancer
for statistically significant RR, OR or SMR strictly
above 5.
Consulted bibliographical databases included: Medline
(National Library of Medicine, USA), Cochrane Library
(Wiley Interscience, USA), Pascal - Institut national de
l’information scientifique et technique (National scientific
and technical information institute, France), National
Guideline Clearinghouse (Agency for Healthcare Research
and Quality, USA), Guidelines Finder (National Library
for Health, USA).
We also consulted a number of websites: INRS, InVS,
HAS (French National Authority for Health), Lemanis-
sier medical library, National Institute for Health andClinical Excellence, Scottish Intercollegiate Guidelines
Network, The National Cancer Institute for Occupatio-
nal Safety and Health (NIOSH) and the websites pub-
lished by learned societies involved in the project.
We also used other sources of information: the biblio-
graphical references quoted in analysed articles, recom-
mendations (Canadian, German and American) on the
screening of bladder cancer, the National Toxicology
Program classification of chemical carcinogenic substan-
ces and the European Union of Dangerous Substances
classification.
Concerning occupational risk factors, only publications
in English and French were selected, all dating from
1950 to 1st September 2011, by using the following key
words: "urinary bladder neoplasms”, “bladder neoplasm”,
“bladder cancer”, “bladder tumour”, “occupational dis-
eases”, “occupation”, "occupational exposure”, “work”,
“latency”, “natural history”, “treatment”, “sensitivity”,
specificity”, “screening” and all key words concerning
bladder carcinogens and activities potentially exposing
to bladder carcinogens (“aromatic amines”, “polycyclic
aromatic hydrocarbons”, “nitrosamines”, “rubber indus-
try”, “dye industry”, “tannery”, “leather”, “leather in-
dustry”, “hairdressers”, “chemical industry”, “chemical
plants”, “laboratory”, “research laboratory”, “printing in-
dustry”, “aluminium”, “aluminium reduction plant”, “alu-
minium production”, “aluminium industry”, “coal tar
pitch”, “Söderberg”, “foundry”, “steel”, “iron”, “tar”, “tar
distillation”, “distillery”, “creosote”, “calcium carbide”,
“coal gasification”, “coal”, “gas workers”, “shale oils”,
“carbon black”, “carbon”, “electrode”, “electrode manu-
facturing”, “coke”, “coke industry”, “coke production”,
“roofer”, “waterproofer”, “bituminen”, “diesel”, “diesel ex-
hausts”, “diesel engine exhausts”, “gasoline”, “gasoline
engine exhausts”, “paint”, “painter”, “varnish” “lacquer”.).
Concerning bladder cancer screening tests, we exclu-
sively selected publications in English and French, all
dating from 1990 to 1st September 2011 by using, the
key words: “screening”, “urinary tests”, “fluorescence im-
munocytochemistry urinary test”, “urinary cytology”,
“NMP 22”, “NMP22BC test”, “Fluorescence In Situ Hy-
bridisation”, “FISH, “Fibrinogen Degradation Products”,
“Bladder Tumour Antigen”, “cytokeratin”, “fibroblast
growth factor receptor”, “microsatellites”. A total of 2,278
references were obtained. The first selection of articles
was based on the title and abstract to include only meta-
analysis, systematic reviews, cohort studies which were
"well-conducted" (i.e. taking into account confounding
factors and potential dose–response relationships) and
case–control studies for which occupational exposure
was clearly described. A total of 682 articles was fi-
nally analysed. All consulted sources (except Canadian,
German and American recommendations) contained
peer-reviewed data.
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prising 4 members from the SFMT (French Society for
Occupational Health) designated by their own society,
2 oncologists designated by the SFC (French Cancer
Society), 3 urologists designated by the AFU (French
Urology Association), one member from the INRS (French
Research and Safety Institute), one member from the InVS
(French Institute for Public Health Surveillance), occupa-
tional physicians, general practitioners, epidemiologists, a
biologist, an anatomopathologist and members of patient
associations.
The first draft of proposed recommendations was read
by a reading group comprised of 87 healthcare pro-
fessionals (1 member from the Direction Générale du
Travail (General Directorate for Labour), 1 member
from the Caisse Nationale d’Assurance Maladie des Tra-
vailleurs Salariés, Direction des Risques Professionnels
(French health insurance fund for salaried workers - Pro-
fessional risks directorate), 48 occupational physicians
(medical practitioners, university hospital practitioners
and screening institution practitioners), 5 work and labour
inspection practitioners, 12 general practitioners, 9 urolo-
gists, 5 oncologists, 7 representatives from partner social
institutions and 3 research and prevention engineers),
with a response rate of 84.6%. Readers were asked to crit-
ically comment the working group’s argumentation and to
grade their agreement with its formulated recommenda-
tions (1 in the case of total disagreement, 9 in the case of
total agreement). The draft was therefore revised where
appropriate by the working group according to readers’
comments. The final version of the recommendation ar-
gumentation was analysed by the HAS good professional
practice recommendation committee and the HAS scien-
tific college.
Since no human being was involved in this study, no
Ethics Committee or Institutional Review Board appro-
val was necessary. For the same reason, no written in-
formed consent was necessary.
Results
Table 2 and Table 3 summarise the results of analysis
of the scientific literature concerning identification of
carcinogenic risk groups (Table 2 defines categories of
workers to be discussed for inclusion in a targeted
bladder cancer screening programme. Table 3 defines
categories of workers for whom high exposure to occu-
pational bladder carcinogens has generally been estab-
lished without specific published epidemiological studies
on bladder cancer risk in these groups of workers). We
have chosen to list the occupations or sectors of activity
associated with increased bladder cancer risk, rather than
the incriminated chemical agents, in order to render the
table more suitable for use by occupational physicians
(or general practitioners/urologists), when defining theirmedical surveillance strategy. As expected, risk level after
analysis of the literature is very high with a high degree of
proof for rubber industry workers and dye manufacturing
workers. Risk level is high for plastics industry workers if
exposed to 4,4’-methylene bis (chloroaniline) (MBOCA),
for workers involved in the production of 4-chloro-ortho-
toluidine-based pesticides, but also for textile industry
(dyeing) workers and for leather and tanning industry
workers. Moderate risk levels are observed for many occu-
pations, such as hairdressers and assimilated professions,
workers exposed to coal combustion soot or painters. Sur-
prisingly, for certain workers, such as road surfacing
workers, workers using coal-tar creosotes, calcium carbide
production workers, shale oil extraction workers or coke
manufacturing workers, there was insufficient data to es-
tablish risk level after analysis of the literature, even if high
exposure to occupational bladder carcinogens has gener-
ally been established for these workers.
Table 4 summarises the results of the performance of
proposed and marketed urinary tests for diagnosing blad-
der cancer, their availability, acceptability, adverse effects
and cost. In this table, data including confidence intervals
for sensitivity and specificity of urinary cytology, FISH,
ImmunoCyt and NMP22 for the detection and follow-up
of bladder cancer, result from a systematic review con-
ducted in 2010 by the National Institute for Health
Research (NIHR), and published as part of its Health
Technology Assessment (HTA) programme [189]. Among
the marketed urinary tests likely to be used in targeted
bladder cancer screening, the fluorescence immunocyto-
chemistry urinary test is the one that offers the best sensi-
tivity all tumour stages and grades combined (evaluated at
84% [IC 95%, 77–91]) [189], whereas urinary cytology of-
fers the best specificity all tumour stages and grades com-
bined (above 90%) [189-197].
In studies focusing on the sensitivity and the specificity
of the urinary tests used combined, sensitivity is above
that of any one test used alone (whereas specificity is, of
course, lower than that of one test used alone). The com-
bination of urinary cytology and fluorescence immuno-
cytochemistry considerably increases sensitivity (mean:
85%), compared to urinary cytology alone, in particular for
the detection of low-grade tumours. The average specifi-
city of the two tests combined is 70% [192,195,197,209].
The high cost of fluorescence immunocytochemistry
and its limited availability (laboratory tests cannot be
used during medical consultations and are performed by
only a few French laboratories) mean that it is not the
choice test for monitoring bladder carcinogen-exposed
workers within a context of targeted screening of blad-
der cancer of occupational origin.
We conducted performance simulations for the differ-
ent screening tests proposed (and combinations thereof ),
on a population of 100,000 male subjects aged from 50
Table 2 Worker categories to be discussed for inclusion in a targeted bladder cancer screening programme
Targeted occupational group
(main references)
Position Level of risk after analysis
of the literature*
Period of exposure in France
Rubber industry workers (level of proof 1)
[14-27]
- rubber production workers, using 4-aminobiphenyl
and/or β-naphtylamine and its salts and/or MBOCA
VERY HIGH Generally before 1989
Before 1950 for subjects exclusively exposed to
β-naphtylamine and its salts
Principle exposing positions in rubber and tyre
manufacturing include weighing and mixing, finishing
and storage, baking or vulcanisation exposing workers
to PAHs and nitrosamines.
Before 1970 for subjects exclusively exposed to
4-aminobiphenyl
However: harmful residual carcinogenic substances
(PAHs and nitrosamines in particular) remained in use
in the rubber industry beyond the 1980s.
Dye manufacturing workers (level of proof
1) [28-46]
- workers in the production of benzidine and/or
benzidine-derived and/or auramine-derived and/or
ortho-toluidine-derived and/or magenta-derived and/or
o-dianisidine-derived and/or o-tolidine-derived and/or
3,3'-dichlorobenzidine-derived and/or 2-methoxy 5
methylaniline-derived colouring agents
VERY HIGH Generally before 1989
Before 1980 for subjects exclusively exposed to
benzidine
Before 1990 for subjects exclusively exposed to
ortho-toluidine
- subjects working in production workshops where the
aforementioned products are used
Principle exposing activities include: preparation and
weighing activities; pigment, colouring agent, paint and
varnish manufacturing; quality control, sampling,
laboratory and cleaning positions.
Textile industry (dyeing) workers (level of
proof 3 to 4) [47-50]
- yarn dyed fabric workers HIGH Before 1970
However: harmful residual carcinogenic substances
(PAHs and nitrosamines in particular) remained in use
in the textile dyeing industry beyond the 1970s.
Leather and tanning industry workers (level
of proof 3) [51-56]
- leather shoe and/or boot manufacturing workers HIGH Before 1990
- leather shoe and/or boot repair workers
- tanning, leather goods, leather processing workers
Targeted occupational group (main
references)
Position Level of risk after analysis
of the literature*
Period of exposure
Plastics industry workers, if exposed to
4,4’-methylene bis (chloroaniline)
(MBOCA) [57-69]
- workers using epoxy and polyurethane resin
hardening agents
HIGH Since the 1950s and still in use today
- subjects working in workshops where epoxy and
polyurethane resin hardening agents are used
Workers involved in the production of
4-chloro-ortho-toluidine-based pesticides
(level of proof 2) [70]
- chlordimeform production workers HIGH Before 1986
- subjects working in workshops where chlordimeform
has been produced
Workers involved in aluminium production
(level of proof 1) [71-89]
aluminium production workers having used the
Søderberg process
HIGH Before 1989





















Table 2 Worker categories to be discussed for inclusion in a targeted bladder cancer screening programme (Continued)
Textile industry (weaving) workers (level of
proof 2 to 3) [47-50]
Hairdressers and assimilated professions
(level of proof 2) [90-98]
- hairdressers MODERATE Before 1980
- barbers
- beauticians
Workers involved in the plastics industry in
general [57-69]
-production agents (after detailed assessment of
specific exposure to carcinogenic agents, PAHs in
particular)
MODERATE To the present day
Chemical and pharmaceutical industry
workers [99-107]
-production agents (after detailed assessment of
specific exposure to carcinogenic agents)
MODERATE To the present day
Printing industry workers [108-111] - ink manufacturing MODERATE Before 1970
- printers
Targeted occupational group (main
references)
Position Level of risk after analysis
of the literature*
Period of exposure
Iron and/or steel foundry workers [112-120] - iron and/or steel production workers (casting and/or
knockout in particular)
MODERATE To the present day
Workers exposed to coal combustion soot
[95,121]
- chimney sweeps MODERATE To the present day
- coal fire boiler room workers and those having
manufactured coal nuts
Before 2007
Workers involved in coal gas production
[122-124]
- coal gas production workers MODERATE Before 1970
Roof waterproofing work [125-128] - roofers MODERATE To the present day
- waterproofing workers
Workers exposed to diesel engine exhaust
fumes [129-132]
- professional diesel engine vehicle drivers: (heavy-
goods vehicle drivers, public transport drivers, taxi
drivers, work site vehicle drivers, diesel locomotive
drivers)
MODERATE To the present day
- motor vehicle mechanics
- automobile control technicians (MOT/inspection)
- 2-wheeled vehicle delivery drivers
- police officers
- tollbooth attendants
Metalworkers or fitters exposed to cutting
oils and fluids [133-140]
- metal machining workers MODERATE To the present day
- tool-dressers
- adjusters (tasks: machining, cutting, welding,
degreasing, maintenance/trimming)






















Table 2 Worker categories to be discussed for inclusion in a targeted bladder cancer screening programme (Continued)
Transport vehicle repair and construction
[95,139,150,151]
- tool-dressers MODERATE To the present day
- adjusters
Dry cleaning workers [152-159] dry cleaning workers MODERATE To the present day
Wine growers [160] - use of arsenic-based pesticides MODERATE Before 2001
* VERY HIGH relative risk for relative risks (RR), Odds ratios (OR) or Standardised Mortality Ratios (SMR) observed in the scientific literature strictly above 5; HIGH relative risk for RR, OR or SMR strictly above 2 and equal





















Table 3 Categories of workers for whom high exposure to occupational bladder carcinogens has generally been
established without specific epidemiological studies on the risk of bladder cancer in these groups of workers
Targeted occupational group
(main references)
Position Level of risk after analysis of
the literature*
Period of exposure
Research laboratory workers [161-167] Genetic engineering, nuclear biology,
mutagenesis and cancerogenesis
laboratories, weighing activities, use of
reagents and synthetic intermediates*
Insufficient data to establish
risk level
To the present day
Road surfacing workers [125-128] Asphalt spreaders, gritters, compactors Insufficient data to establish
risk level
Up to the late 1980s
Workers using coal-tar creosotes
[112,168-170]
Workers conducting specific wood
treatment activities
Insufficient data to establish
risk level
To the present day
Calcium carbide production workers [171] Production workers* Insufficient data to establish
risk level
Up to the mid 2000s
Shale oil extraction workers [172] Shale oil extraction workers Insufficient data to establish
risk level
To the present day
Carbon black production workers
[50,173-176]
Manufacturing workers* Insufficient data to establish
risk level
To the present day
Carbon electrode manufacturing workers
[177-179]
Manufacturing workers* Insufficient data to establish
risk level
To the present day
Coke manufacturing workers
[125-128,180-186]
Cokers Insufficient data to establish
risk level
To the present day
Carbon nut industry [187] Manufacturing workers* Insufficient data to establish
risk level
To the present day
Carbon disc manufacturing [188] Manufacturing* and
maintenance workers
Insufficient data to establish
risk level
To the present day
Clay pigeon manufacturing [188] Manufacturing workers* Insufficient data to establish
risk level
To the present day
Cement oven repair [188] Manufacturing workers* Insufficient data to establish
risk level
To the present day
Work on water conveyance conducts
coated with varnish containing HAP [188]
Technicians/repair workers* Insufficient data to establish
risk level
To the present day
Glazing in aluminium foundries [188] Glazers Insufficient data to establish
risk level
To the present day
*After detailed assessment of specific exposure to carcinogenic agents.
Table 4 Proposed and marketed urinary tests for bladder cancer screening: summary of performance, availability,
acceptability, adverse effects
Test/dosage Sensitivity Specificity Main references
Detection of haematuria using a
reactive test strip
46 to 74% for one test, If test repeated
over several days: 90 to 95%
51 to 84% [190,198-202]
Urinary cytology ▪ For all tumour grades and stages: 44%
[CI 95%, 38–51] [203]
▪ For all tumour grades and stages:
96% [CI 95%, 94–98] [203]
[191-197,203,204]
▪ For Carcinoma in situ (Cis) 70 to 90% ▪ For Cis: 90%
NMP22BC test ▪ For all tumour grades and stages: 65%
[CI 95%, 50–80] [203]
▪ For all tumour grades and stages:




- Grade G1: 83.9%
- Grade G3: 62.5%
Fluorescence immunocytochemistry
(ImmunoCyt™/uCyt + ™)
▪ For all tumour grades and stages: 84%
[CI 95%, 77–91] [203]
▪ For all tumour grades and stages:
75% [CI 95%, 68–83] [203]
[189,203,210-213]
FISH (Fluorescence In Situ
Hybridisation) UroVysion™ Kit
▪ For all tumour grades and stages: 76%
[CI 95%, 65–84] [203]
▪ For all tumour grades and stages:
75% [CI 95%, 78–92] [203]
[189,191,192,203,214-218]
▪ For Cis and G3: >95%
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http://www.biomedcentral.com/1471-2458/14/1155to 74 years, based on their degree of exposure to bladder
carcinogens (refer to Additional file 1: Table S1). Bladder
cancer incidence in this population was 54.6 cases/
100,000. In the absence of sufficient data, the sensitivity
and specificity of test combinations were calculated as
if the test had been conducted independently. The
NMP22BC test, exclusive haematuria testing and combi-
nations of urine cytology with, respectively, the NMP22BC
test and haematuria test, generated an extremely high
proportion of false positive results (around 20,000 false
positives for 100,000 subjects, in each high-risk group cat-
egory). If we extrapolate these results to a population of
750,000 subjects concerned by potential targeted screen-
ing in France (subjects at a high and very high risk of blad-
der cancer), the number of false positives likely to be
generated by these tests would be 300,000. Urinary cy-
tology used alone would generate 8,000 false positives for
100,000 high or very high risk subjects which, in our
population of 750,000 subjects, corresponds to 60,000
false positive results. Although very high, this figure is well
below the 300,000 observed with the previously described
tests.
The sensitivity of urinary cytology alone is mediocre
all stages combined (mean: 44%, see Table 4), hence gen-
erating a large number of false negatives. Nevertheless,
the sensitivity of this technique is the best for high
grades (mean: 80%, see Table 4), which require early
diagnosis since late-stage cancers are of very poor prog-
nosis, hence rendering it the choice option for first line
targeted screening strategies.
Discussion
In 2005, a panel of international experts (International
Consensus Panel on cytology and bladder tumour mar-
kers) concluded that individual screening in high-risk
patients (smokers, occupationally-exposed subjects, sub-
jects with a genetic predisposition) could be considered
using, in particular, urinary makers associated or not
with conventional cytology. In this indication, although
no currently marketed tumour markers appear suitable
for replacing cytoscopy, tests such as fluorescence im-
munocytochemistry, combined with cytology, microsa-
tellites or FISH (Fluorescence In Situ Hybridisation) are
of genuine interest, offering high sensitivity and a nega-
tive predictive value of 95%, hence avoiding unnecessary
cytoscopies [13].
The main diagnostic limitation of urinary markers is
their specificity, which is lower than that of conventional
cytology and behind a substantial number of false posi-
tive results; they are also costly. In certain studies, the
performance of the various tests likely to be used for
bladder cancer screening were compared on the same
patient: for each comparison, urinary cytology offered
lower sensitivity, all grades combined, than the markerwith which it was compared, whilst offering higher sen-
sitivity for high-grade tumours and higher specificity
whatever the grade.
Since several studies on bladder cancer screening tools
are currently underway, the present recommendations
will require to be reassessed according to results of new
and ongoing studies.
The various aforementioned observations led the French
team to put forward the following recommendations:
– The high cost of fluorescence immunocytochemistry
and its limited availability (laboratory tests cannot
be used during medical consultations and are
performed by only a few French laboratories) mean
that it is not the choice test for monitoring bladder
carcinogen-exposed workers within a context of
targeted screening of bladder cancer of occupational
origin.
– Given its poor performance, in terms of both
sensitivity and specificity, it is recommended to
avoid the exclusive detection of microscopic
haematuria using reactive urinary test strips during
specific follow-up consultations for targeted
screening of subjects currently or previously
occupationally exposed to carcinogens.
– Repeated detection of microscopic haematuria using
reactive urinary strips (daily test over 5 days, then
weekly test over 51 weeks or daily test over 14 days
then, in the absence of haematuria, daily test over
14 days - 9 months later) offers good sensitivity
[194]. However, the constraints involved in its
implementation (urinary strip packaging, uncertainty
on user compliance) do not enable it to be
considered as a choice examination within the
context of the follow-up of workers exposed to
bladder carcinogens for the targeted screening of
bladder cancer of occupational origin.
– Urinary cytology (or urinary cytodiagnosis), the aim
of which is to detect tumour cells originating from
bladder or urinary tract cancer and desquamating in
urine, is the urinary test with the best specificity
(for all tumour grades and stages - on average, above
90%, see Table 4), and with the best sensitivity for
high-grade tumours, requiring urgent medical care,
hence its first-line use.
– According to current knowledge, the combination of
urinary cytology and urinary tests such as the
NMP22BC test cannot be recommended within
targeted screening procedures.
Proposal for the medical follow-up of workers currently
or previously exposed to bladder carcinogens
In populations presenting with a high risk of bladder
cancer subsequent to occupational exposure justifying
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http://www.biomedcentral.com/1471-2458/14/1155targeted screening, screening tests are recommended
20 years after the start of exposure to the bladder car-
cinogen (GRADE B recommendation, “Scientific proof
presumed”).
Urinary cytology among subjects currently or previ-
ously exposed to bladder carcinogens is recommended
for subjects included in a targeted screening programme
(expert consensus).
A 6-month periodicity is recommended for conducting
targeted bladder cancer screening tests among subjects
currently or previously occupationally exposed to blad-
der carcinogens (expert consensus).
The proposed medical surveillance protocol accounts
for the performance of the various screening tests (speci-
ficity/sensitivity) and, in particular, the expected number
of false positive results for the monitored population.
This protocol is summarised in the following algorithm
(Table 5) (expert consensus):
 RECOMMENDED (in all cases): for groups of
workers with a very high risk of bladder cancer
i.e. RR > 5 (see Table 2), or professions with
documented high exposure levels (Table 3), with
an exposure duration equal to or in excess of
1 year;
 PROPOSED (for discussion on a case-by-case basis):Tabl
expo
Minim– for groups of workers with a very high risk of
bladder cancer (see Table 2) or professions
with documented high exposure levels
(Table 3), with an exposure duration of less
than 1 year;
– for groups of workers with a high risk of bladder
cancer (Table 2) with an exposure duration equal
to or in excess of 1 year; NOT RECOMMENDED (in view of the
performance of currently available tests) for groups
of workers with a moderate risk of bladder cancer
(Table 2), and for groups of workers with a high risk
of bladder cancer (Table 2), with an exposure
duration of less than 1 year.e 5 Algorithm summarising the recommended medico-pr
sed to carcinogenic substances for the bladder
Risk level for the professional group Group of workers w
HIGH risk (RR or OR
or professions with
high exposure
Exposure duration ≥ 1 year
Follow-up RECOMMENDED
um latency period after the start of exposure
Proposed first line, then 6-monthly testSubsequent to the compilation of these recommen-
dations, a few new articles have been published [219].
Indeed, authors analysed the performance of FISH
(Fluorescence In Situ Hybridisation) in combination
with NMP22 for bladder cancer screening in this popu-
lation. They observed that the combination of these 2
tests detected more cases than cytology alone, at the
expense of a lower specificity, and concluded that it
cannot be recommended to apply these markers for
screening in asymptomatic workers, given that the in-
crease in sensitivity is not balanced by the high cost of
FISH and the false-positive results obtained by NMP22.
Another recent study on occupational urinary tract
cancers in Great Britain described the same types of oc-
cupational exposure associated with bladder cancer as
those compiled in our own study [220].
Conclusion
Occupational cancer prevention relies first and foremost
on primary prevention, in other words, not only the
identification of carcinogenic substances present in the
working environment, but also on the evaluation of indi-
vidual and collective exposure, hence enabling the imple-
mentation of measures aimed at eliminating/controlling
these substances. Such prevention implies accurate risk
assessment, taking into account current scientific know-
ledge on modes of action, dose-effect relationships and on
the potential existence of an effect threshold, in order to
enable the reduction and the traceability of occupational
exposure. Such traceability must offer workers the benefits
of improved knowledge in terms of information on tox-
icity and medical follow-up. Certain authors have even
established a guideline to assess occupational bladder can-
cer risk. For example, a German research group has pro-
vided a multilingual questionnaire on occupational and
further bladder cancer risk factors [221]. This question-
naire asks for relevant medical information, for the occu-
pational history since leaving school and for intensity and
frequency of certain occupational and non-occupational
risk factors. In another study, the authors established a
guideline specifically evaluating occupational bladder can-
cer risk for compensation [222].ofessional follow-up of workers currently or previously
ith a VERY
or SMR > 5)
documented
levels
Group of workers with
a HIGH risk (2< RR or
OR or SMR ≤5)
Group of workers with
a MODERATE risk
(1< RR or OR or SMR ≤2)
< 1 year ≥ 1 year < 1 year
PROPOSED NOT RECOMMENDED (in view of the
performance of currently available tests)
20 years
Urinary cytology
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http://www.biomedcentral.com/1471-2458/14/1155Even if no study has relied on a sufficient sample of
individuals to assess the relevance of bladder cancer
screening in populations at risk, we are convinced of the
necessity to implement recommendations that rely on
analysis of the scientific literature to provide a more
rational definition of medical surveillance modalities
for subjects currently or previously exposed to bladder
carcinogens.
Nevertheless, an evaluation of the benefits of this tar-
geted screening strategy for bladder cancer is recom-
mended. Given ongoing research on the different urinary
markers for potential use in targeted bladder cancer
screening, analysis of the feasibility and the performance
of a targeted bladder screening programme combining
urinary cytology and other urinary markers is recom-
mended within a 5-year timescale.
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